0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

CHEMOTHERAPY OF LEPROSY

G. H. FAGET, M.D.; PAUL T. ERICKSON, M.D.
JAMA. 1948;136(7):451-457. doi:10.1001/jama.1948.02890240017005.
Text Size: A A A
Published online

Early in 1941 a new drug, "promin," was introduced in the treatment of leprosy at the National Leprosarium. After several months' treatment of a few patients with this drug rather decided improvement occurred in their specific leprous lesions. In November 1943 the "promin" treatment of leprosy was first reported in the medical literature1 and was regarded as the most encouraging experimental treatment ever undertaken at the National Leprosarium. Since then "promin" and its related sulfones, "diasone" and "promizole," have been used extensively in the treatment of leprosy with exceedingly good results.

At the Second Pan-American Leprosy Conference held in Rio de Janeiro, Brazil, in October 1946, the Subcommittee on Therapeutics took cognizance of the divergent opinions on the effect of chaulmoogra oil and its derivatives in the treatment of leprosy.2 The committee advised that the efficacy of chaulmoogra oil be reevaluated. Simultaneously, it recognized the sulfone drugs as

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();